Given the premise that TSP-1 serves as a regulator of neuronal activity-driven glioma growth, we sought to target TSP-1 therapeutically using gabapentin (GBP), which blocks the thrombospondin receptor α2δ-1 (ref. 47). This evidence concerns the gene THBS1 and central nervous system cancer.